Buying momentum slowed considerably after Moderna (MRNA) shares topped $80.00. The management's timing of a stock sale worsened investor trust. Since the $87.00 peak in May 2020, markets lack any momentum or confidence to buy the stock. The company is up "only" four-fold from its 52-week low. By contrast, the latest billion-dollar funding for Novavax (NVAX) sends the stock to a $111.77 intra-day high, and up a mouth-watering 2,700% from yearly lows.
Novavax is up in stock price terms but has a lower total valuation by market capitalization. For both stocks to rise from here, the companies must post encouraging clinical results data. What do investors like about Novavax's NVX-CoV2373 vaccine candidate?
READ FULL ARTICLE HERE
